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ABSTRACT 1 
 2 
Renal phosphate handling critically determines plasma phosphate and whole body 3 
phosphate levels. Filtered phosphate is mostly reabsorbed by Na+-dependent 4 
phosphate transporters located in the brush border membrane of the proximal tubule: 5 
NaPi-IIa (SLC34A1), NaPi-IIc (SLC34A3), and Pit-2 (SLC20A2). Here we review new 6 
evidence for the role and relevance of these transporters in inherited disorders of 7 
renal phosphate handling. The importance of NaPi-IIa and NaPi-IIc for renal 8 
phosphate reabsorption and mineral homeostasis has been highlighted by the 9 
identification of mutations in these transporters in a subset of patients with infantile 10 
idiopathic hypercalcemia (IIH) and patients with Hereditary Hypophosphatemic 11 
Rickets with Hypercalciuria (HHRH). Both diseases are characterized by disturbed 12 
calcium homeostasis secondary to elevated 1,25-(OH)2 vitamin D3 as a consequence 13 
of hypophosphatemia. In vitro analysis of mutated NaPi-IIa or NaPi-IIc transporters 14 
suggests defective trafficking underlying disease in most cases. Monoallelic 15 
pathogenic mutations in both SLC34A1 and SLC34A3 appear to be very frequent in 16 
the general population and have been associated with kidney stones. Consistent with 17 
these findings, genome-wide association studies indicate that variants in SLC34A1 18 
are associated with a higher risk to develop kidney stones and chronic kidney 19 
disease but underlying mechanisms have not been addressed to date.  20 
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Systemic phosphate balance depends on renal excretion 1 
 Phosphate is the third most abundant anion in the human body and accounts 2 
for about 1% of total body mass. Approximately 80-85 % of total phosphate content is 3 
stored in bone in the form of apatite, contributing to bone stability, about 15 % is 4 
distributed in soft tissues, and only 1 % is contained in the rapidly exchangeable 5 
plasma pool.  6 
 Phosphate balance depends on dietary intake and intestinal absorption, 7 
distribution between organs, and renal filtration and reabsorption. As discussed 8 
below, it is mainly renal handling that is tightly regulated and thereby exerts ultimate 9 
control over whole body phosphate homeostasis. The recommended daily allowance 10 
(RDA) for phosphate is age-dependent. Infants are recommended to receive daily 11 
about 100-275 mg and children and adolescents 460-1250 mg/day [1]. In growing 12 
children phosphate balance should be positive to support building of bone and 13 
growth of soft tissues. In adults, intestinal net absorption and renal net excretion 14 
should ultimately remain zero to avoid phosphate overload or deficiency, 15 
respectively. However, in most industrialized countries phosphate content of food 16 
exceeds RDA [2-4].  17 
 The mechanisms underlying intestinal phosphate absorption are not fully 18 
elucidated. At present, experimental evidence from humans and animal models 19 
supports a bimodal pathway consisting of a transcellular, transporter-dependent 20 
pathway and a poorly defined paracellular route [5]. The transcellular route involves 21 
the sodium-driven phosphate transporter NaPi-IIb (Npt2b, SLC34A2) mostly 22 
expressed in the jejunum in humans [6-7]. The expression of the transporter is 23 
regulated by dietary phosphate intake and 1,25 (OH)2 vitamin D3 [8-10]. However, the 24 
overall contribution of this transporter to intestinal phosphate absorption may be low, 25 
at least under normal phosphate intake, as evident from mouse models deficient for 26 
NaPi-IIb/Slc34a2 and from humans with the rare inborn condition of pulmonary 27 
alveolar microlithiasis caused by loss-of-function mutations in SLC34A2/NaPi-IIb [8, 28 
11-12]. NaPi-IIb depleted mice do not suffer from hypophosphatemia or any other 29 
obvious sign of systemic phosphate deficiency unless challenged with a low 30 
phosphate diet [8, 13-14]. During low Pi availability, NaPi-IIb deficient mice become 31 
highly hypercalciuric, at least in part due to increased osteoclast activity providing 32 
phosphate to the organism at the expense of bone density [14]. In humans with 33 
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SLC34A2 mutations, no detailed analysis of phosphate balance has been reported to 1 
date. Two other phosphate transporters, PiT1 (SLC20A1) and PiT2 (SLC20A2) are 2 
also expressed in the small and large intestine at rather low levels and their role and 3 
contribution to intestinal phosphate absorption are unknown. Patients with mutations 4 
in SLC20A2 develop basal ganglia calcifications but no other symptoms relating to 5 
systemic phosphate homeostasis have been reported [15].  6 
 7 
Renal phosphate transporters 8 
 Renal phosphate excretion depends on the filtered load of phosphate and its 9 
subsequent reabsorption along the nephron. There is no evidence for active 10 
secretion of phosphate into urine. The bulk of tubular phosphate reabsorption occurs 11 
in the proximal tubule with some evidence pointing also to a smaller component of 12 
active reabsorption in segments between the late proximal tubule and the connecting 13 
tubule [16]. 14 
 In the proximal tubule, at least three different sodium-driven phosphate 15 
transporters mediate the initial step of phosphate reabsorption across the apical 16 
brush border membrane: NaPi-IIa (Npt2a, SLC34A1), NaPi-IIc (Npt2c, SLC34A3), 17 
and PiT2 (SLC20A2) (Figure 1) [17-18]. As discussed below, all evidence suggests 18 
that NaPi-IIa and NaPi-IIc play important roles in humans and rodent models but 19 
possibly to different extent. The basolateral exit pathway for phosphate remains 20 
unknown but may involve a mechanism of anion exchange [19-20]. Also, the 21 
molecular identity of potential phosphate transporter(s) in the more distal nephron 22 
segments has not been reported. 23 
 The three phosphate transporters expressed in the proximal tubule exhibit 24 
different transport modes, sensitivity to pH, and dynamics of regulation by dietary 25 
phosphate intake and phosphaturic hormones. Briefly, NaPi-IIa and NaPi-IIc transport 26 
divalent phosphate (HPO42-) whereas PiT2 prefers monovalent phosphate (H2PO4-). 27 
Moreover, NaPi-IIa and PiT2 mediate electrogenic transport of phosphate because of 28 
their coupling of the transport cycle to 3 or 2 Na+ ions, respectively, leading to the net 29 
translocation of one positive charge per phosphate ion. NaPi-IIc transports only 2 Na+ 30 
ions per phosphate and is therefore electroneutral (Figure 1). Domains in NaPi-IIa 31 
and NaPi-IIc involved in sodium and phosphate binding have been identified [21]. 32 
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 Because of their different sensitivity to extracellular protons and preferred 1 
phosphate species (di- vs monovalent phosphate), NaPi-IIa and NaPi-IIc operate 2 
most efficiently at a near neutral pH (~ pH 7.4 – 7.0) whereas PiT2 would become 3 
more active at slightly more acidic conditions [18, 22]. 4 
 5 
Inherited forms of renal phosphate wasting 6 
 Renal phosphate wasting can occur as part of several systemic syndromes, 7 
generalized inherited or acquired dysfunction of the proximal tubule (e.g. Debre-8 
DeToni-Fanconi syndrome) and in a number of inherited disorders specifically 9 
affecting renal and extrarenal phosphate homeostasis (for review see [23-24]). Most 10 
inherited extrarenal disorders leading to changes in renal phosphate handling are 11 
caused by mutations in FGF23 or factors controlling FGF23 levels or sensitivity of 12 
target cells. Thus, disorders like X-linked hypophosphatemia (XLH; PHEX mutations), 13 
autosomal dominant hypophosphatemic rickets (ADHR; FGF23 mutations), familial 14 
tumoral calcinosis (FTC; GALNT3 or FGF23 mutations), fibrous dysplasia (McCune-15 
Albright syndrome; GNAS mutations), osteoglophonic dysplasia (FGF-receptor 1 16 
(FGFR1) mutations), osteosclerotic bone dysplasia (Raine syndrome; FAM20c), or 17 
autosomal recessive hypophosphatemic rickets (ARHR; DMP1 or ENPP1 mutations), 18 
also known as autosomal recessive hypophosphatemia (ARHP), are primarily 19 
extrarenal disorders affecting renal phosphate handling [23-26].  20 
 In contrast, mutations in NaPi-IIa, NaPi-IIc and maybe also in NHERF1 (Na/H 21 
exchanger factor 1) directly affect the renal capacity to reabsorb phosphate. The 22 
roles of two other proteins potentially involved in renal phosphate handling, PiT2 and 23 
XPR1, are currently unclear even though mutations in both genes have been 24 
described in patients. . 25 
 Mutations in SLC34A1 and SLC34A3 cause nephrocalcinosis and kidney 26 
stones. The pathogenesis of nephrocalcinosis in the setting of various inherited and 27 
acquired kidney diseases has recently been reviewed in much detail [27-30]. The 28 
pathophysiology underlying nephrocalcinosis in patients with SLC34A1 and 29 
SLC34A3 is thought to be caused by the primary loss of phosphate with urine, the 30 
consecutive stimulation of 1,25 (OH)2 vitamin D3 synthesis leading to enhanced 31 
intestinal calcium absorption and calcium overload. Renal excretion of calcium 32 
Genetic defects of renal phosphate handling 
 
6 
 
causes hypercalciuria which together with elevated urinary phosphate levels can 1 
trigger the formation of calcium-phosphate containing crystals favoring the 2 
development of renal calcifications.  3 
 NaPi-IIa (SLC34A1) 4 
 SLC34A1 has been linked to phosphate homeostasis in humans by several 5 
lines of evidence. A genome wide association study (GWAS) for determinants of 6 
serum phosphate levels identified SLC34A1 among other genes including FGF23 7 
and the Calcium-sensing receptor CaSR [31]. Similarly, GWAS for nephrolithiasis in a 8 
sample of an adult Japanese population linked to a region near 5q35.3, implicating 9 
SLC34A1 (located at this site) in calcium phosphate kidney stone disease [32-34]. 10 
Also the Icelandic genome analysis consortium identified SLC34A1 next to the CaSR 11 
and alkaline phosphatase as a risk gene for kidney stones and identified one specific 12 
marker within SLC34A1 as being associated with hypophosphatemia and low PTH 13 
[35]. 14 
 Homozygous and (compound) heterozygous mutations, or small insertions 15 
and deletions in SLC34A1 were independently identified by several laboratories 16 
when investigating adult patients with kidney stones and reduced bone density [36] 17 
or pediatric patients with either hypophosphatemia and hyperphosphaturia [37], 18 
infantile idiopathic hypercalciuria [38], or with nephrocalcinosis and kidney stones 19 
[35, 39-44]. Larger deletions including the SLC34A1 gene can occur as part of Sotos 20 
syndrome characterized by learning deficiencies, facial dysmorphia, overgrowth, 21 
hypercalcemia, and nephrocalcinosis [45].  22 
 Up to date, 29 distinct mutations have been identified in SLC34A1, mostly 23 
causing missense mutations, small in-frame deletions, frame shifts or early stop-24 
codons resulting in a truncated transporter (Figure 2A, Supplementary Table 1) [35-25 
37, 39-42, 44, 46]. Interestingly, most of these mutations appear to be located within 26 
regions predicted to be part of the transmembrane domains of the transporter. These 27 
regions are often highly conserved in transport proteins and are more sensitive to 28 
changes in their structure. Several of these mutated proteins were expressed and 29 
functionally analyzed in heterologous expression systems such as Xenopus oocytes 30 
or the opossum kidney (OK) cell line resembling the proximal tubule. Collectively, 31 
these studies show reduced function of mutated transporters mostly due to trafficking 32 
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defects, with mutant proteins retained intracellularly [37-38, 41]. However, one 1 
mutation is of particular interest: a small in-frame deletion of 7 amino acids at the N-2 
terminus of NaPi-IIa (91del7) was identified in several patients as either one of two 3 
mutated alleles (compound heterozygous patients) or as homozygous mutation in at 4 
least one patient [38]. All these patients show symptoms similar to patients with other 5 
pathogenic mutations suggesting that this mutation is deleterious. However, in vitro 6 
analysis in Xenopus oocytes shows no obvious transport defect [38, 47] whereas 7 
expression of the mutant protein in OK cells suggested reduced apical expression 8 
and partial retention, pointing to a possible trafficking defect [38]. Interestingly, 9 
inspection of public data bases like ExAC shows a high allele frequency of 0.018 10 
suggesting that approximately 2 % of the general population are heterozygous 11 
carriers of this mutation. The combined allele frequency of all proven pathogenic 12 
exonic mutations is 0.022 whereas the total allele frequency of all nucleotide changes 13 
leading to an altered amino acid sequence sums up to 0.07. The relevance of this 14 
finding is currently unclear but may link to an increased risk of developing calcium 15 
phosphate kidney stones in adulthood.  16 
 In pediatric patients, SLC34A1 mutations were mostly homozygous or 17 
compound heterozygous and the pattern of inheritance was autosomal recessive. No 18 
obvious pathology was detected in parents or other family members carrying only 19 
one affected allele. In contrast, three adult patients were described with only one 20 
allele mutated and presenting with calcium phosphate stones and reduced bone 21 
density [36]. However, no further genetic information was available and considering 22 
the relatively high frequency of stone disease and its association with reduced bone 23 
density in the adult population, it remains unclear whether the symptoms in these 24 
patients were caused by SLC34A1 mutations. Moreover, detailed functional analysis 25 
of the two reported gene variants yielded no obvious defect [48]. Also, in other 26 
families of affected homozygous patients, heterozygous carriers did not present with 27 
a high frequency of kidney stones suggesting that heterozygosity per se may not 28 
cause a higher risk for kidney stones [37]. However, GWAS clearly support a role of 29 
SLC34A1 in stone disease [32-33, 35]. NaPi-IIa interacts with itself by forming 30 
homodimers of two transporters [49]. Both subunits function independently in the 31 
healthy state [50]. It is unknown at which cellular level the interaction occurs (e.g. at 32 
the level of the endoplasmic reticulum, Golgi or plasma membrane) and whether 33 
interaction of a normal transporter with a mutant transporter may accelerate 34 
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degradation or reduce membrane insertion. Interactions between normal and mutant 1 
transporter could reduce overall expression of NaPi-IIa by up to 75 % and thereby 2 
help explaining some of the clinical observations made in heterozygous carriers of 3 
NaPi-IIa mutations. Thus, it remains to be examined whether additional genetic or 4 
environmental factors together with the presence of one mutated allele may cause a 5 
higher risk for kidney stone disease.  6 
 Indeed, a mouse model of Slc34a1 deficiency presents calcium phosphate 7 
and calcium oxalate containing renal calcifications when challenged with high 8 
phosphate or oxalatediets [51-52]. Slc34a1 KO mice like human patients with 9 
SLC34A1 mutations are hypercalciuric [38, 53]. The renal loss of phosphate 10 
stimulates activation of 1,25(OH)2 vitamin D3 by the renal 1-alpha-hydroxylase 11 
(CYP27B1) and reduces inactivation by the 24-hydroxylase (CYP24A1). The 12 
elevated levels of 1,25(OH)2 vitamin D3 stimulate intestinal phosphate and calcium 13 
absorption. The latter is excreted by the kidney causing hypercalcuria and an 14 
increased risk of nephrolithiasis and –calcinosis. Consistently, restricted 1,25(OH)2 15 
vitamin D3 synthesis (or lower vitamin D3 supply) and enhanced phosphate 16 
supplementation reduces renal calcifications [54]. Thus, children with SLC34A1 17 
mutations likely benefit from phosphate supplements and should not receive 18 
standard vitamin D3 supplements during the first years of life. Whether mutation of 19 
one allele is sufficient to trigger a similar mechanism is currently unknown but may 20 
depend, among other factors, on dietary supply of vitamin D3, phosphate, and 21 
calcium.  22 
 23 
 NaPi-IIc (SLC34A3) 24 
 Mutations in SLC34A3 are the cause of hereditary hypophosphatemic rickets 25 
with hypercalciuria (HHRH) [55-57]. In contrast to patients with mutations in 26 
SLC34A1, rickets is a common feature along with hypophosphatemia, 27 
hyperphosphaturia, hypercalciuria, and elevated 1,25(OH)2 vitamin D3. 28 
Consequently, many patients develop kidney stones or nephrocalcinosis. It appears 29 
that problems persist into adulthood whereas the clinical symptoms in patients with 30 
SLC34A1 mutations may improve with reaching adulthood suggesting that NaPi-IIa 31 
may play a more prominent role in earlier phases of life and NaPi-IIc may be the 32 
more important transporter in adult kidney (in contrast to rodents where NaPiIIc 33 
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appears to be mostly expressed during growth). However, this is based only on few 1 
observations and longer follow-ups are required in patients with the different 2 
mutations. 3 
 Up to date, 32 different mutations in SLC34A3 have been reported [55-70] 4 
including mostly missense mutations, mutations affecting potential splice sites, and 5 
smaller and larger deletions causing premature stop codons with expression of a 6 
truncated transporter (Figure 2B, supplementary table 2). Some of these mutations 7 
have been further characterized using in vitro expression systems and found to 8 
cause mostly retention in the endoplasmic reticulum, but also to reduce the stability in 9 
the plasma membrane, or to decrease transport activity [57-58, 62] similar to findings 10 
for SLC34A1 mutations. Proven pathogenic SLC34A3 mutations (allele frequency 11 
0.002) are less frequent in the general population than for SLC34A1. However, when 12 
considering suspected mutations (e.g. without clear genetic or experimental proof) 13 
total allele frequency increases to 1.5 but mostly due to two very frequent allele 14 
variants with nearly 0.4 and 0.8 allele frequency. At this point, the relevance for NaPi-15 
IIc activity is unclear and requires better genetic and experimental proof to provide 16 
insights whether these alleles may contribute to an increased risk to develop kidney 17 
stones as discussed above for SLC34A1. 18 
 Different mouse models of NaPi-IIc deficiency have been created to further 19 
examine the role of the transporter and to gain better insights into the pathology of 20 
HHRH. A constitutive Slc34a3 KO mouse model showed normal growth, no evidence 21 
for renal phosphate losses, was normophosphatemic and had normal bone growth 22 
and morphology [71]. However, NaPi-IIc KO mice had hypercalcemia, hypercalciuria 23 
and high levels of 1,25(OH)2 vitamin D3, whereas FGF23 is reduced [71]. A second 24 
mouse model with an inducible deletion of renal NaPi-IIc was generated to examine 25 
whether acute or chronic compensatory mechanisms may mask some of the 26 
expected pathology in the constitutive KO mouse. Surprisingly, inducible NaPi-IIc KO 27 
mice showed no biochemical abnormalities and had similar levels of calcium in 28 
plasma and urine as well as normal 1,25(OH)2 vitamin D3 and FGF23. No evidence 29 
for compensation by other renal phosphate transporters, i.e. NaPi-IIa or PiT2, was 30 
found [72].   31 
 32 
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NHERF1 1 
 NHERF1, also known as PDZK3 or Binding Protein 50 (EBP50), is encoded by 2 
the SLC9A3R1 gene and acts as a scaffold protein for brush border membrane 3 
associated proteins in the proximal tubule. Among its binding partners are NaPi-IIa, 4 
the parathyroid hormone receptor 1 and phospholipase C [73-78]. NHERF1 stabilizes 5 
these proteins at the brush border membrane and creates a platform for PTH 6 
signaling to NaPi-IIa [73-74, 79-81]. Prie and colleagues reported in total 8 patients 7 
with hyperphosphaturia and kidney stone disease carrying heterozygous gene 8 
variants in NHERF1 [82-83]. Expression of the L110V, R153Q, and E225K gene 9 
variants in cell culture models increased PTH responsive downregulation of NaPi-IIa 10 
[82]. The E68A variant was reported to disrupt the interaction with NaPi-IIa possibly 11 
leading to destabilization of the transporter at the brush border membrane [83]. Of 12 
note all patients were only heterozygous carriers of the reported variants and as 13 
noted by others the same gene variants are found at high frequency in public 14 
databases, raising the question whether the observed gene variants are causative for 15 
disease [84]. Also, mice lacking only one copy of NHERF1 show no major 16 
abnormalities [78, 81].     17 
 18 
Other renal phosphate transporters 19 
 The kidney expresses at least two further proteins that may also participate in 20 
renal phosphate transport: PiT2 (SLC20A2) and XPR1 (xenotropic and polytropic 21 
retrovirus receptor 1).  22 
 SLC20A2 23 
 The expression and localization of PiT2 has been described in some detail in 24 
rodent kidney. PiT2 localizes to the brush border membrane of the proximal tubule, 25 
colocalizing with NaPi-IIa and NaPi-IIc [85-86]. More recently, a subset of patients 26 
with familial idiopathic basal ganglia calcification, a specific form of primary brain 27 
calcifications, was shown to harbor mutations in SLC20A2 [15, 87]. However, no 28 
renal phenotype or disorders related to phosphate homeostasis, but other defects, 29 
have been reported to date. Thus, the role of SLC20A2 in renal phosphate handling 30 
and inherited disorders of mineral balance remains to be examined. 31 
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 XPR1 1 
   XPR1 has been linked to phosphate transport based on its homology to plant 2 
and yeast phosphate transporters, on harboring an SPX domain found in various 3 
plants, yeast and bacterial proteins involved in cellular phosphate homeostasis, and 4 
on the modulation of phosphate efflux from plant and mammalian cells with XPR1 5 
deficiency or overexpression [88-89]. It has been suggested that XPR1 may be part 6 
of the long-sought basolateral efflux pathway in epithelial cells of the kidney and 7 
small intestine and/or may participate in cellular phosphate sensing [90]. Indeed, 8 
XPR1 mRNA expression is high in kidney and small intestine in rodents. However, 9 
definite proof is lacking regarding the basolateral expression of XPR1 in kidney and 10 
intestinal epithelia, as well as its implication in the actual transport pathway and/or 11 
cellular phosphate sensor in mammalian cells. The data presented to date clearly 12 
support a role in cellular phosphate homeostasis but conclusions are mostly based 13 
on experiments from plant cells, yeast or prokaryotic systems. Interestingly, 14 
mutations in XPR1 are also found in some patients with familial idiopathic basal 15 
ganglia calcification [91-92]. However a renal involvement has not been reported to 16 
date.   A recent study with an inducible kidney-specific Xpr1 KO mouse demonstrated 17 
a very severe disease with symptoms of a generalized proximal tubular defect, mild 18 
hypophosphatemia and bone disease [93]. However, the study did not provide 19 
definite answers to the question whether XPR1 is part of the basolateral phosphate 20 
efflux pathway.  21 
 22 
GLUT2 (SLC2A2) 23 
 Patients from two consanginous families were reported that presented with 24 
hypophosphatemic rickets and renal phosphate wasting in the one family and with a 25 
generalized proximal tubulopathy including hypercalciuria and only mildy increased 26 
urinary phosphate excretion in the second family [94]. Genetic analysis revealed two 27 
novel homozygous mutations, IVS4-2A>G and R124S, in the SLC2A2 gene encoding 28 
the GLUT2 glucose transporter. GLUT2 is localized at the basolateral side of 29 
proximal tubule cells and serves as main exit pathway for glucose. Mutations in 30 
SLC2A2 are the cause of the Fanconi-Bickel syndrome that includes a generalized 31 
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dysfunction of proximal tubule cells with urinary loss of low molecular weight proteins, 1 
bicarbonate, glucose, and phosphate [95-96]. Of interest, mice lacking Glut2 in 2 
kidney showed greatly reduced expression levels of NaPiIIa and NaPiIIc at least in 3 
part explaining the urinary phosphate loss [94]. Thus, mutations of genes such as 4 
that affect the general function of the proximal tubule may also cause renal 5 
phosphate losses as in Dent's disease due to mutations in CLCN5 or ORCL [97-98]. 6 
 7 
Relevance of SLC34A1 for chronic kidney disease 8 
 Genome-wide association studies have linked SLC34A1 to the risk for 9 
developing chronic kidney disease [99-100]. This association has been replicated in 10 
large cohorts with different ethnic background and shows a very high significance 11 
[101-102]. Progression of kidney disease has been shown to associate with reduced 12 
SLC34A1 mRNA and protein expression in human kidney biopsies [103]. However, 13 
whether the reduced SLC34A1 is cause or consequence of kidney disease remains 14 
unclear. Detailed functional analysis of the genetic loci linking SLC34A1 to CKD risk 15 
and development of suitable animal models may be needed to unravel the nature of 16 
this association. Also, the frequency of SNPs in the general population and in 17 
patients with CKD has to be examined to determine the relevance of SLC34A1 for 18 
CKD. Nevertheless, the fact that rare pathogenic mutations in SLC34A1 cause 19 
nephrocalcinosis and progressive loss of renal function, at least in some patients, 20 
may suggest that less severe alterations in SLC34A1 function may contribute to a 21 
slower loss of kidney function in adults.  22 
 23 
Summary and outlook 24 
 The kidney is the gate-keeper of systemic phosphate homeostasis and the 25 
severe alterations in mineral homeostasis found in patients with mutations in key 26 
players of renal phosphate handling underline this notion. Biallelic mutations in the 27 
coding regions of the renal phosphate transporters SLC34A1 (NaPi-IIa) and 28 
SLC34A3 (NaPi-IIc) cause massive renal phosphate loss leading to secondary 29 
elevation of 1,25(OH)2 vitamin D3 and hypercalciuria, driving the development of 30 
nephrolithiasis or   -calcinosis predisposing to progressive loss of renal function. 31 
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Surprisingly, monoallelic pathogenic mutations in SLC34A1 and SLC34A3 are 1 
relatively frequent in the general population. Whether carriers of these mutations may 2 
have a higher risk for developing kidney stones remains to be fully established. 3 
Moreover, SLC34A1 is associated with the risk for developing CKD in the general 4 
population but mechanisms and its relevance to overall CKD risk remain to be 5 
examined.    6 
 7 
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Figure legends 1 
Figure 1 2 
Scheme of renal phosphate handling: (A) Renal phosphate reabsorption occurs 3 
mostly in the proximal segments of the nephron (orange). The segmental localization 4 
of all three known apical phosphate transporters is schematically shown in the 5 
nephron models. (B) Immunolocalization of NaPi-IIa, NaPi-IIc and Pit-2 in rat kidney 6 
under phosphate depleted conditions showing expression of NaPi-IIa in early and 7 
late segments of the proximal tubule whereas NaPi-IIc and Pit-2 are localized only in 8 
the early proximal tubule. High magnification of early proximal tubules with NaPi-IIa, 9 
NaPi-IIc and Pit-2 stained in green, brush border membranes are marked in red 10 
showing colocalization (yellow). Some NaPi-IIa molecules are also seen in 11 
intracellular compartments presumably in the Golgi apparatus. (C) Model of a 12 
proximal tubule cell, with NaPi-IIa, NaPi-IIc, and Pit-2 localized in the brush border 13 
membrane, mediating Na+-dependent reabsorption of phosphate. Phosphate 14 
reabsorption is mostly energized by the activity of basolateral Na+/K+-ATPases. The 15 
basolateral exit pathway for phosphate is not well defined. 16 
Figure 2  17 
Predicted models of NaPi-IIa (SLC34A1) and NaPi-IIc (SLC34A3) and localization of 18 
mutations identified in patients. For details on mutations and references see 19 
supplementary tables.  20 
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Supplementary table 1 
SLC34A1 Mutations 
Position Functionality Disease Refs 
A48F Dominant negative 
inhibition of transport ? 
Nephrolithiasis and 
low bone density 
[1] 
91del7 Mild trafficking defect Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2-3] 
A133V Not tested Nephrocalcinosis [4-5] 
P146L Not tested Nephrocalcinosis [4] 
V147M Dominant negative 
inhibition of transport ? 
Nephrolithiasis and 
low bone density 
[1] 
G153V 
G153A 
Trafficking defect Infantile idiopathic 
hypercalemia 
Nephrocalcinosis  
[2, 4] 
I154_V160dup Small duplication 
 
Fanconi-like 
syndrome 
[6] 
L155P Trafficking defect Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2-3] 
L179P Not tested Nephrolithiasis 
Hypercalciuria 
[5] 
I185fs Frame shift Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2] 
IVS6(+1)g>a Not tested Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2, 5] 
R215W Trafficking defect Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2, 7] 
W305* Large truncation Infantile idiopathic 
hypercalemia 
Nephrocalcinosis  
[2] 
IVS9(+3_6)del Not tested Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2] 
IVS9(+1)g>a Not tested Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2] 
C336G Trafficking defect Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2] 
G402R Not tested Nephrolithiasis 
Hypercalciuria 
[5] 
V408E Trafficking defect Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2] 
IVS12(+5)g>a Not tested Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2] 
G450S Not tested Nephrocalcinosis [4] 
I456B Not tested Nephrocalcinosis [4] 
I475 fs Frame shift with 
trafficking defect 
Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2] 
C476Sfs Frame shift, not tested Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[3] 
W488R Trafficking defect Infantile idiopathic 
hypercalemia 
Nephrocalcinosis 
[2] 
Y489C Not tested Nephrolithiasis, low 
PTH, 
hypophosphatemia 
[8] 
R495H Trafficking defect Nephrocalcinosis, 
Hypophosphatemia 
[9] 
R512C Not tested Nephrolithiasis [10] 
W538* Large truncation Infantile idiopathic 
hypercalemia 
Nephrocalcinosis  
[2] 
T575I Not tested Nephrolithiasis 
Hypercalciuria 
[5] 
 
Supplementary table 2 
SLC34A3 Mutations 
Position Functionality Disease Refs 
Q49X Large truncation HHRH [11] 
c.175+1 G>A Changes the first nt of 
the donor splice site of 
intron 3 (E59) 
HHRH [12] 
c.228delC  Frame shift in A76 
codon, introducing a 
early stop codon. 
Large truncation 
HHRH [13] 
G78R Not tested HHRH [14] 
c.304+2T→C Disrupts an essential 
residue at the donor 
splice site of intron 4  
HHRH [15] 
c.367delC 
(counting contains 
the 5’UT) 
Premature termination 
after residue p.P48 
HHRH [16] 
T137M Impaired expression 
and function 
HHRH [17] 
S138F Reduced membrane 
stability 
HHRH [13, 18] 
g.1226G>A 
(IVS5 + 1G>A 
Affects the splice 
donor site of intron 5 
HHRH [19] 
S168F Not tested HHRH [20] 
R182W Not tested HHRH [21] 
g.1440–1469del Deletion in intron 6: 
mRNA decay? 
HHRH [22] 
G191R Not tested HHRH [23] 
S192L Not tested HHRH [13, 15] 
G196R ER retention HHRH [13, 15, 18] 
c.744delC Frame shift after codon 
for H248, introducing 
an early stop codon 
HHRH [15] 
c.757-1G>A Affects the splice 
donor site of intron 7 
HHRH [24] 
c.1046_47del Frame-shift that 
introduces 242 
unrelated amino acids 
in the C-terminus 
HHRH [22] 
g.2259_2359del Deletion of 101 bp 
within intron 9. 
Aberrant RNA splicing 
HHRH [13, 25]  
R353L Not tested HHRH [15] 
g.2615–2699del Deletion of 85 bp 
within intron 10. 
Aberrant RNA splicing 
HHRH [25] 
W412R Not tested HHRH [12] 
A413E Not tested HHRH [15] 
c.1304delG Frame shift in codon 
for S435, introducing a 
premature stop codon 
HHRH [26] 
g.4225_50del Deletion of the last 25 
bp of intron 12 and the 
first bp of exon 13, 
which introduces a 
stop codon after V446. 
Abolished membrane 
expression 
HHRH [17] 
F453del Not tested HHRH [16] 
G457S Not tested HHRH [16] 
R468W ER retention  [13, 18] 
c.1571_1880del Truncation leading to 
frame shift in codon for 
L524, introducing a 
premature stop codon 
HHRH [22] 
L527del Not tested HHRH [13]   
R564C Reduced membrane 
stability 
HHRH [18] 
Y588X Not tested HHRH [22] 
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